CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS

News provided by

Aug 12, 2022, 07:00 ET

ROCKVILLE, Md. and BEIJING, Aug. 12, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the second quarter of 2022.

Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, commented, "We are pleased to report $8.6 million in EVOMELA^®sales revenue for the second quarter of 2022. This is an increase of 19% compared to the same period last year. Our sales and marketing team is proven to be resilient, rapidly adapting strategies to address COVID-19 related challenges to ensure that our priories remain on track."

Dr. He continued, "Equipped with experience from EVOMELA and the ability to adapt to a changing environment, I believe our commercial and medical marketing team can efficiently execute the anticipated launch of CNCT19 in China. In addition, we continue to progress on the development and regulatory framework for BI-1206 in China. The BI-1206 trial in China has been initiated, and we expect to dose the first patient in the second half of this year."

Second Quarter 2022 Financial Highlights

Revenues consist primarily of product sales of EVOMELA. Revenue was $8.6 million for the three months ended June 30, 2022, compared to $7.2 million for the three months ended June 30, 2021.
Costs of revenues were $3.6 million for the three months ended June 30, 2022, compared to $3.0 million for the three months ended June 30, 2021, which included royalty payment of $1.7 million and $1.4 million, respectively.
Research and development expenses for the three months ended June 30, 2022, were $3.9 million, compared with $2.3 million for the three months ended June 30, 2021. The increase of research and development expenses for the three months periods was mainly due to expense incurred for CID-103.
General and administrative expenses for the three months ended June 30, 2022, were $5.5 million, compared with $5.5 million for the three months ended June 30, 2021.
Selling and marketing expenses for the three months ended June 30, 2022, were $3.4 million, compared with $3.4 million for the three months ended June 30, 2021.
Acquired in-process R&D expenses for the three months ended June 30, 2022, were $0, compared with $1.06 million for the three months ended June 30, 2021.
As of June 30, 2022, CASI had cash and cash equivalents of $18.9 million.

Further information regarding the Company, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, can be found at www.casipharmaceuticals.com.

Conference Call

The conference call can be accessed by dialing 1-866-218-2402 (U.S.) or 1-412-902-6605 (International) and ask to be joined into the CASI Pharmaceuticals call to listen to the live conference call. Confirmation #10169302.

This call will be recorded and available for replay by dialing 1-877-344-7529 (U.S.) or 1-412-317-0088 (International) and enter 9173539 to access the replay.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The majority of the Company's operations are now located in China. The Company is focused on acquiring, developing, and commercializing products that augment its hematology/oncology therapeutic focus as well as other areas of unmet medical need. The Company is executing its plan to become a biopharmaceutical leader by launching medicines in the greater China market, leveraging its China-based regulatory, clinical and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. The Company has built a commercial team of more than 100 hematology and oncology sales and marketing specialists based in China. More information on CASI is available at www.casipharmaceuticals.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations, and goals. Forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on The Nasdaq Capital Market; the volatility in the market price of our common stock; the outbreak of the COVID-19 pandemic and its effects on global markets and supply chains; the risk of substantial dilution of existing stockholders in future stock issuances; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates, including with respect to BI-1206, CB-5339 and CID-103; our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the U.S. Food and Drug Administration (FDA), National Medical Products Administration (NMPA), or other regulatory authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates, including with respect to our partnerships with Juventas and BioInvent; the risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the risks associated with our product candidates, and the risks associated with our other early-stage products under development; the risk that result in preclinical and clinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; our ability to protect our intellectual property rights; our ability to design and implement a development plan for our ANDAs held by CASI Wuxi; the lack of success in the clinical development of any of our products; and our dependence on third parties; the risks related to our dependence on Juventas to conduct the clinical development of CNCT19 and to partner with us to co-market CNCT19; risks related to our dependence on Juventas to ensure the patent protection and prosecution for CNCT19; risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); risks relating to interests of our largest stockholders and our Chairman and CEO that differ from our other stockholders; and risks related to the development of a new manufacturing facility by CASI Wuxi. Such factors, among others, could have a material adverse effect upon our business, results of operations, and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition, and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

EVOMELA^® is proprietary to Acrotech Biopharma Inc. and its affiliates.

COMPANY CONTACT:
Rui Zhang
CASI Pharmaceuticals, Inc.
Phone: 240.864.2643
Email: [email protected]

(Financial Table Follows)

CASI Pharmaceuticals, Inc.
Unaudited Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)

	June 30, 2022		December 31, 2021
ASSETS
Current assets:
Cash and cash equivalents	$	18,862	$	38,704
Investment in equity securities, at fair value		5,705		9,868
Accounts receivable, net of $0 allowance for doubtful accounts		10,260		9,803
Inventories		5,791		1,907
Prepaid expenses and other		1,666		1,688
Total current assets		42,284		61,970

Property, plant and equipment, net		14,853		12,712
Intangible assets, net		10,952		12,203
Long-term investments		41,671		40,128
Right of use assets		8,462		9,107
Other assets		635		2,178
Total assets	$	118,857	$	138,298

LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	4,598	$	4,789
Accrued and other current liabilities		7,576		8,397
Bank borrowings		1,001		—
Total current liabilities		13,175		13,186

Deferred income		2,658		2,828
Other liabilities		13,420		14,325
Total liabilities		29,253		30,339

Commitments and contingencies

Redeemable noncontrolling interest, at redemption value		22,661		23,457

Stockholders' equity:
Preferred stock, $1.00 par value: 5,000,000 shares authorized and 0 shares issued and		—		—
outstanding
Common stock, $0.01 par value:
250,000,000 shares authorized at June 30, 2022 and December 31, 2021
13,733,459 shares and 13,987,578 shares issued at June 30, 2022 and December 31, 2021, respectively;
13,606,130 shares and 13,979,624 shares outstanding at June 30, 2022 and December 31, 2021, respectively		1,373		1,399
Additional paid-in capital		695,369		694,826
Treasury stock, at cost: 127,329 shares and 7,954 shares held at June 30, 2022 and December 31, 2021		(9,068)		(8,034)
Accumulated other comprehensive income		(160)		1,954
Accumulated deficit		(620,571)		(605,643)
Total stockholders' equity		66,943		84,502
Total liabilities, redeemable noncontrolling interest and stockholders' equity	$	118,857	$	138,298

CASI Pharmaceuticals, Inc.
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)

	Three Months Ended June 30				Six Months Ended June 30
	2022		2021		2022		2021
Revenues:
Product sales	$	8,550		7,125	$	17,575	$	12,825
Lease income from a related party		23		37		60		73
Total revenues		8,573		7,162		17,635		12,898

Costs of revenues:
Cost of goods sold		1,865		1,537		3,842		2,774
Royalty fee		1,685		1,445		3,466		2,566
Total costs of revenues		3,550		2,982		7,308		5,340

Gross Profit		5,023		4,180		10,327		7,558

Operating expenses:
Research and development		3,851		2,255		7,843		7,513
General and administrative		5,520		5,488		10,845		10,990
Selling and marketing		3,398		3,360		6,675		6,075
Acquired in-process research and development		—		1,055		—		6,555
Total operating expenses		12,769		12,158		25,363		31,133

Loss from operations		(7,746)		(7,978)		(15,036)		(23,575)

Non-operating income (expense):
Interest income, net		40		76		114		182
Other income		11		33		49		53
Foreign exchange gain		1,355		76		1,688		295
Change in fair value of investments		(1,153)		1,914		(2,708)		3,482
Impairment loss of long-term investments		—		(865)		—		(865)
Loss before income tax expense		(7,493)		(6,744)		(15,893)		(20,428)
Income tax expense		—		—		—		—
Net loss		(7,493)		(6,744)		(15,893)		(20,428)
Less: loss attributable to redeemable noncontrolling interest		(548)		(317)		(965)		(666)
Accretion to redeemable noncontrolling interest redemption value		735		519		1,348		1,067
Net loss attributable to CASI Pharmaceuticals, Inc.	$	(7,680)	$	(6,946)	$	(16,276)	$	(20,829)

Net loss per share (basic and diluted)	$	(0.56)	$	(0.50)	$	(1.19)	$	(1.57)
Weighted average number of common stock outstanding (basic and diluted)		13,606,130		13,979,636		13,700,282		13,235,128

Comprehensive loss:
Net loss	$	(7,493)	$	(6,744)	$	(15,893)	$	(20,428)
Foreign currency translation adjustment		(3,541)		1,005		(3,293)		833
Total comprehensive loss	$	(11,034)	$	(5,739)	$	(19,186)	$	(19,595)
Less: Comprehensive loss attributable to redeemable noncontrolling interest		(1,800)		14		(2,144)		(403)
Comprehensive loss attributable to common stockholders	$	(9,234)	$	(5,753)	$	(17,042)	$	(19,192)